



NDA 018013/S-064

**SUPPLEMENT APPROVAL**

Mallinckrodt Inc.  
Attention: Donatus Ako-Arrey  
Director, Regulatory Affairs  
675 McDonnell Blvd. 30-2  
Hazelwood, MO 63042

Dear Mr. Ako-Arrey:

Please refer to your Supplemental New Drug Application (sNDA) dated and received November 28, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Pamelor (nortriptyline HCl) 10 mg, 25 mg, 50 mg, 75 mg oral capsules.

This Prior Approval supplemental new drug application provides for the addition of “Brugada Syndrome” to the Warnings section, Adverse Reactions section, and the Medication Guide.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email Simran Parihar, PharmD, at [simran.parihar@fda.hhs.gov](mailto:simran.parihar@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Tiffany R. Farchione, MD  
Director (Acting)  
Division of Psychiatry Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

### **ENCLOSURE(S):**

Content of Labeling  
Prescribing Information  
Medication Guide

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

TIFFANY R FARCHIONE  
04/09/2019 10:43:59 AM